

Amparo Larrauri

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3211375/amparo-larrauri-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

65

papers

3,108

citations

22

h-index

55

g-index

77

ext. papers

4,163

ext. citations

9.6

avg, IF

4.53

L-index

| # | Paper | IF | Citations |
|----|--|------|-----------|
| 65 | Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. <i>Lancet, The</i> , 2018 , 391, 1285-1300 | 40 | 1109 |
| 64 | First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020. <i>Eurosurveillance</i> , 2020 , 25, | 19.8 | 310 |
| 63 | A surveillance network for meningococcal disease in Europe. <i>FEMS Microbiology Reviews</i> , 2007 , 31, 27-36 | 5.1 | 118 |
| 62 | Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. <i>Vaccine</i> , 2005 , 23, 4097-100 | 4.1 | 115 |
| 61 | Excess all-cause mortality during the COVID-19 pandemic in Europe - preliminary pooled estimates from the EuroMOMO network, March to April 2020. <i>Eurosurveillance</i> , 2020 , 25, | 19.8 | 114 |
| 60 | I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe. <i>PLoS ONE</i> , 2011 , 6, e27622 | 3.7 | 79 |
| 59 | Excess all-cause and influenza-attributable mortality in Europe, December 2016 to February 2017. <i>Eurosurveillance</i> , 2017 , 22, | 19.8 | 79 |
| 58 | Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study. <i>BMJ, The</i> , 2020 , 371, m4509 | 5.9 | 73 |
| 57 | I-MOVE multicentre case-control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination?. <i>Eurosurveillance</i> , 2016 , 21, | 19.8 | 65 |
| 56 | Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15. <i>Eurosurveillance</i> , 2016 , 21, pii=30139 | 19.8 | 59 |
| 55 | Influenza surveillance in Europe: comparing intensity levels calculated using the moving epidemic method. <i>Influenza and Other Respiratory Viruses</i> , 2015 , 9, 234-46 | 5.6 | 53 |
| 54 | European all-cause excess and influenza-attributable mortality in the 2017/18 season: should the burden of influenza B be reconsidered?. <i>Clinical Microbiology and Infection</i> , 2019 , 25, 1266-1276 | 9.5 | 50 |
| 53 | Assessing the burden of paediatric influenza in Europe: the European Paediatric Influenza Analysis (EPIA) project. <i>European Journal of Pediatrics</i> , 2010 , 169, 997-1008 | 4.1 | 49 |
| 52 | Seasonality and geographical spread of respiratory syncytial virus epidemics in 15 European countries, 2010 to 2016. <i>Eurosurveillance</i> , 2018 , 23, | 19.8 | 48 |
| 51 | Dominant influenza A(H3N2) and B/Yamagata virus circulation in EU/EEA, 2016/17 and 2017/18 seasons, respectively. <i>Eurosurveillance</i> , 2018 , 23, | 19.8 | 44 |
| 50 | Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies. <i>Eurosurveillance</i> , 2018 , 23, | 19.8 | 43 |
| 49 | Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019. <i>Eurosurveillance</i> , 2019 , 24, | 19.8 | 41 |

| | | | |
|----|--|------|----|
| 48 | Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011-2012 season in Spain, among population targeted for vaccination. <i>BMC Infectious Diseases</i> , 2013 , 13, 441 | 4 | 40 |
| 47 | Estimating the burden of seasonal influenza in Spain from surveillance of mild and severe influenza disease, 2010-2016. <i>Influenza and Other Respiratory Viruses</i> , 2018 , 12, 161-170 | 5.6 | 33 |
| 46 | Real-time monitoring shows substantial excess all-cause mortality during second wave of COVID-19 in Europe, October to December 2020. <i>Eurosurveillance</i> , 2021 , 26, | 19.8 | 33 |
| 45 | Estimating the influenza vaccine effectiveness in elderly on a yearly basis using the Spanish influenza surveillance network--pilot case-control studies using different control groups, 2008-2009 season, Spain. <i>Vaccine</i> , 2010 , 28, 2903-7 | 4.1 | 30 |
| 44 | Influenza coverages in Spain and vaccination-related factors in the subgroup aged 50-64 years. <i>Vaccine</i> , 2003 , 21, 3550-5 | 4.1 | 23 |
| 43 | Influenza-related mortality in Spain, 1999-2005. <i>Gaceta Sanitaria</i> , 2012 , 26, 325-9 | 2.2 | 22 |
| 42 | Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15-64-year-olds in Europe: exploration by birth cohort. <i>Eurosurveillance</i> , 2019 , 24, | 19.8 | 22 |
| 41 | Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season. <i>Eurosurveillance</i> , 2017 , 22, | 19.8 | 21 |
| 40 | Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents, Spain, weeks 53 2020 to 13 2021. <i>Eurosurveillance</i> , 2021 , 26, | 19.8 | 21 |
| 39 | 2015/16 I-MOVE/I-MOVE+ multicentre case-control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among children. <i>Influenza and Other Respiratory Viruses</i> , 2018 , 12, 423-437 | 5.6 | 21 |
| 38 | Epidemiology of the 2009 influenza pandemic in Spain. The Spanish Influenza Surveillance System. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2012 , 30 Suppl 4, 2-9 | 0.9 | 20 |
| 37 | 2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project. <i>Eurosurveillance</i> , 2017 , 22, | 19.8 | 20 |
| 36 | Infection fatality risk for SARS-CoV-2: a nationwide seroepidemiological study in the non-institutionalized population of Spain | | 20 |
| 35 | Using surveillance data to estimate pandemic vaccine effectiveness against laboratory confirmed influenza A(H1N1)2009 infection: two case-control studies, Spain, season 2009-2010. <i>BMC Public Health</i> , 2011 , 11, 899 | 4.1 | 19 |
| 34 | Interim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020. <i>Eurosurveillance</i> , 2020 , 25, | 19.8 | 18 |
| 33 | Waning protection of influenza vaccine against mild laboratory confirmed influenza A(H3N2) and B in Spain, season 2014-15. <i>Vaccine</i> , 2016 , 34, 2371-7 | 4.1 | 18 |
| 32 | Repeated seasonal influenza vaccination among elderly in Europe: Effects on laboratory confirmed hospitalised influenza. <i>Vaccine</i> , 2017 , 35, 4298-4306 | 4.1 | 17 |
| 31 | Climatic Factors and Influenza Transmission, Spain, 2010-2015. <i>International Journal of Environmental Research and Public Health</i> , 2017 , 14, | 4.6 | 17 |

| | | | |
|----|---|------|----|
| 30 | Exploring the effect of previous inactivated influenza vaccination on seasonal influenza vaccine effectiveness against medically attended influenza: Results of the European I-MOVE multicentre test-negative case-control study, 2011/2012-2016/2017. <i>Influenza and Other Respiratory Viruses</i> , 2018 , 12, 567-581 | 5.6 | 15 |
| 29 | Impact of flu on hospital admissions during 4 flu seasons in Spain, 2000-2004. <i>BMC Public Health</i> , 2007 , 7, 197 | 4.1 | 15 |
| 28 | Effectiveness of influenza vaccine against influenza A in Europe in seasons of different A(H1N1)pdm09 and the same A(H3N2) vaccine components (2016-17 and 2017-18). <i>Vaccine: X</i> , 2019 , 3, 100042 | 3.8 | 14 |
| 27 | Interim influenza vaccine effectiveness: A good proxy for final estimates in Spain in the seasons 2010-2014. <i>Vaccine</i> , 2015 , 33, 3276-80 | 4.1 | 14 |
| 26 | Higher vaccine effectiveness in seasons with predominant circulation of seasonal influenza A(H1N1) than in A(H3N2) seasons: test-negative case-control studies using surveillance data, Spain, 2003-2011. <i>Vaccine</i> , 2014 , 32, 4404-4411 | 4.1 | 14 |
| 25 | Effect of previous and current vaccination against influenza A(H1N1)pdm09, A(H3N2), and B during the post-pandemic period 2010-2016 in Spain. <i>PLoS ONE</i> , 2017 , 12, e0179160 | 3.7 | 14 |
| 24 | Determinants of Fatal Outcome in Patients Admitted to Intensive Care Units With Influenza, European Union 2009-2017. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz462 | 1 | 14 |
| 23 | Co-circulation of influenza A(H1N1)pdm09 and influenza A(H3N2) viruses, World Health Organization (WHO) European Region, October 2018 to February 2019. <i>Eurosurveillance</i> , 2019 , 24, | 19.8 | 12 |
| 22 | Exploring the risk of severe outcomes and the role of seasonal influenza vaccination in pregnant women hospitalized with confirmed influenza, Spain, 2010/11-2015/16. <i>PLoS ONE</i> , 2018 , 13, e0200934 | 3.7 | 11 |
| 21 | Influenza pandemic (H1N1) 2009 activity during summer 2009. Effectiveness of the 2008-9 trivalent vaccine against pandemic influenza in Spain. <i>Gaceta Sanitaria</i> , 2011 , 25, 23-8 | 2.2 | 11 |
| 20 | Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021. <i>Eurosurveillance</i> , 2021 , 26, | 19.8 | 11 |
| 19 | Regional excess mortality during the 2020 COVID-19 pandemic in five European countries.. <i>Nature Communications</i> , 2022 , 13, 482 | 17.4 | 8 |
| 18 | Evaluating the impact of the weather conditions on the influenza propagation. <i>BMC Infectious Diseases</i> , 2020 , 20, 265 | 4 | 6 |
| 17 | Vaccine effectiveness against influenza A(H3N2) and B among laboratory-confirmed, hospitalised older adults, Europe, 2017-18: A season of B lineage mismatched to the trivalent vaccine. <i>Influenza and Other Respiratory Viruses</i> , 2020 , 14, 302-310 | 5.6 | 5 |
| 16 | Oseltamivir-resistant pandemic influenza a (H1N1) 2009 viruses in Spain. <i>Journal of Clinical Virology</i> , 2011 , 51, 205-8 | 14.5 | 5 |
| 15 | The Global Epidemiology of RSV in Community and Hospitalized Care: Findings From 15 Countries. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab159 | 1 | 5 |
| 14 | Illness Severity in Hospitalized Influenza Patients by Virus Type and Subtype, Spain, 2010-2017. <i>Emerging Infectious Diseases</i> , 2020 , 26, 220-228 | 10.2 | 4 |
| 13 | Defining the seasonality of respiratory syncytial virus around the world: National and subnational surveillance data from 12 countries. <i>Influenza and Other Respiratory Viruses</i> , 2021 , 15, 732-741 | 5.6 | 4 |

| | | | |
|----|---|------|---|
| 12 | Alternating patterns of seasonal influenza activity in the WHO European Region following the 2009 pandemic, 2010-2018. <i>Influenza and Other Respiratory Viruses</i> , 2020 , 14, 150-161 | 5.6 | 3 |
| 11 | S-adenosyl-L-methionine reverses the cholestatic effect of ethinylestradiol in rat hepatocytes by increasing its catabolism. <i>Cell Biology and Toxicology</i> , 1992 , 8, 13-26 | 7.4 | 3 |
| 10 | Impact of influenza vaccination programmes among the elderly population on primary care, Portugal, Spain and the Netherlands: 2015/16 to 2017/18 influenza seasons. <i>Eurosurveillance</i> , 2019 , 24, | 19.8 | 3 |
| 9 | Understanding influenza vaccination among Portuguese elderly: the social ecological framework. <i>Health Promotion International</i> , 2020 , 35, 1427-1440 | 3 | 2 |
| 8 | Transmissibility of influenza during the 21st-century epidemics, Spain, influenza seasons 2001/02 to 2017/18. <i>Eurosurveillance</i> , 2020 , 25, | 19.8 | 2 |
| 7 | Resistance of microalgae to modern water contaminants as the result of rare spontaneous mutations | | 2 |
| 6 | Impact of Rapid On-demand Molecular Diagnosis of Pediatric Seasonal Influenza on Laboratory Workflow and Testing Costs: A Retrospective Study. <i>Pediatric Infectious Disease Journal</i> , 2019 , 38, 559-563 ^{3,4} | 3.4 | 2 |
| 5 | Impact of national influenza vaccination strategy in severe influenza outcomes among the high-risk Portuguese population. <i>BMC Public Health</i> , 2019 , 19, 1690 | 4.1 | 2 |
| 4 | Perimeter confinements of basic health zones and COVID-19 incidence in Madrid, Spain.. <i>BMC Public Health</i> , 2022 , 22, 216 | 4.1 | 1 |
| 3 | Near real-time surveillance of the SARS-CoV-2 epidemic with incomplete data.. <i>PLoS Computational Biology</i> , 2022 , 18, e1009964 | 5 | 1 |
| 2 | The Impact of COVID-19 on Mortality in Spain: Monitoring Excess Mortality (MoMo) and the Surveillance of Confirmed COVID-19 Deaths.. <i>Viruses</i> , 2021 , 13, | 6.2 | 1 |
| 1 | No effect modification of influenza virus vaccine effectiveness by age or chronic condition was observed in the 2010/11 to 2017/18 seasons. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 1411-1419 ⁶ | 19.6 | 1 |